% | $
Quotes you view appear here for quick access.

Given Imaging Ltd. (GIVN) Message Board

dubi_calmy 29 posts  |  Last Activity: Apr 26, 2015 9:47 AM Member since: Dec 6, 2004
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to


    by starteam003 Apr 17, 2015 6:58 AM
    dubi_calmy dubi_calmy Apr 18, 2015 9:12 AM Flag

    Simple, 1.45+3+2.55=7

  • Reply to


    by starteam003 Apr 17, 2015 6:58 AM
    dubi_calmy dubi_calmy Apr 17, 2015 11:19 AM Flag

    $7 minimum

  • Novartis exec David Epstein says having invested in Israel's Gamida Cell
    and BioLineRx, Novartis is hungry for more.
    Over the past year, Novartis has invested $35 million in Israel’s Gamida Cell,
    with an option to acquire it in the future for $165 million, plus royalties, by mid-2016.
    The investment in Gamida Cell came from our intention to give strategic priority to
    developing cell therapy and gene therapy technologies. Gamida has an advanced
    stem-cell cancer treatment product.
    “The investments are new. Gamida has advanced a lot since we met, the team is
    very talented.

    (Those are a few excerpts from the globes newspaper article)

  • Reply to


    by starteam003 Apr 17, 2015 6:58 AM
    dubi_calmy dubi_calmy Apr 18, 2015 11:58 AM Flag

    Sorry, I am not at liberty to elaborate! Confidential data,
    however having said that, i can add that $7 is the bare

  • Reply to

    Consensus broker rating

    by dubi_calmy Apr 26, 2015 9:46 AM
    dubi_calmy dubi_calmy Apr 26, 2015 9:47 AM Flag

    Shares of Supercom (NASDAQ:SPCB) have received a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that provide coverage for the company, Zacks Investment Research reports. Three equities research analysts have rated the stock with a strong buy recommendation.

  • dubi_calmy by dubi_calmy Apr 26, 2015 9:46 AM Flag

    A number of analysts have recently weighed in on SPCB shares. Analysts at B. Riley initiated coverage on shares of Supercom in a research note on Monday, April 13th. They set a “buy” rating and a $17.75 price target on the stock. Analysts at Singular Research initiated coverage on shares of Supercom in a research note on Tuesday, March 31st. They set a “buy” rating and a $13.25 price target on the stock. Analysts at TheStreet downgraded shares of Supercom from a “buy” rating to a “hold” rating in a research note on Friday, March 27th. Finally, analysts at Feltl & Co. initiated coverage on shares of Supercom in a research note on Friday, March 27th. They set a “strong-buy” rating and a $16.00 price target on the stock.

  • (Partial info, not all up to date, still nice to have been written and mentioned in the media)

    By dmin on February 28, 2015

    The activities Elbit Imaging Ltd. Are in the following major fields split mixed use property projects, predominantly in the retail sector in Central and Eastern Europe and in India, hotels – Hotel ownership, operation, management and sale, primarily in major European cities, Image Guided Treatment – investment in research and development, production and marketing of magnetic resonance imaging guided focused ultrasound treatment equipment, residential Projects – initiation, construction and sale of residential projects and other mixed-use real projects, predominantly residential, in Eastern Europe and in India and Other activities – The distribution and marketing of fashion apparel and accessories in Israel; venture capital investments, Under the heading hospitals and farm and dairy plants in India, which are in preliminary stages..

    GE Healthcare is the marketing authorization holder and distributor of ExAblate in Japan. Kobi Vortman, President and Chief Executive Officer of InSightec, said: The approval of a growing body of evidence showing that ExAblate is a safe, effective and durable treatment for this widespread, life-threatening condition based consequences. ExAblate is an outpatient procedure and patients return is usually home the same day associates associated within 1-2 days as compared to longer hospital stays and recovery times with more invasive procedures such as hysterectomy, myomectomy or UAE.

  • Analysts at Zacks have given a Outperform rating on Pluristem Therapeutics Inc. (NASDAQ:PSTI) with a rating of 1. The counter has received an average rating of 1.67 from 3 brokerage firms. 2 analysts have rated the company as a strong buy. The Counter has been rated as hold from 1 Wall Street Analysts.

    Pluristem Therapeutics Inc. (NASDAQ:PSTI): According to 3 Analysts, The short term target price has been estimated at $ 3.83.The target price could deviate by a maximum of $1.26 from the forecast price. In the near term, the target price could hit a high of $5 and a low of $ 3.

    Company has also disclosed other Insider Buying and Selling activities to the Exchange Commission ., According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the CEO & Chairman of Pluristem Therapeutics Inc, Aberman Zami, had purchased 13,000 shares in a transaction dated on November 11, 2014. The transaction was executed at $2.64 per share with total amount equaling $34,320. N/A

    Shares of Pluristem Therapeutics Inc. (NASDAQ:PSTI) ended the session in red amid volatile trading. The shares closed down 0.13 points or 4.14% at $3.01 with 456,314 shares getting traded. Post opening the session at $3.13, the shares hit an intraday low of $2.99 and an intraday high of $3.17 and the price vacillated in this range throughout the day. The shares had closed the previous day trading session at $3.14. The company has a market cap of $212 million and the number of outstanding shares has been calculated to be 70,528,000 shares. The 52-week high of Pluristem Therapeutics Inc. (NASDAQ:PSTI) is $4.36 and the 52-week low is $2.32.

  • dubi_calmy by dubi_calmy Mar 13, 2015 11:08 AM Flag

    Albeit with less volume!

  • dubi_calmy by dubi_calmy Mar 7, 2015 8:38 AM Flag

    Top Image Systems (NASDAQ:TISA) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a note issued to investors on Friday. The firm currently has a $3.70 price target on the stock. Zacks‘s target price indicates a potential upside of 19.55% from the stock’s previous close.

  • Posted by Erica Dunham on March 4, 2015
    Pluristem Therapeutics, Inc. (NASDAQ:PSTI) should head towards $5.67 per share according to 3 Analysts in consensus. However, if the road gets shaky, the stock may fall short to $4 per share. The higher price estimate target is at $8 according to the Analysts.
    The short interest information of the company was disclosed in the recent information. Pluristem Therapeutics, Inc. (NASDAQ:PSTI) reported a rise of 85% or 345,837 shares in its short interest. The short figure came in at 1.2% of the total floats. The average daily volume of 469,591 shares suggests that the days to cover 752,814 short positions, as on February 13,2015, will be 2. On January 30,2015, the short interest was 406,977 shares.
    Shares of Pluristem Therapeutics, Inc. (NASDAQ:PSTI) appreciated by 2.01% during the past week but lost 18.28% on a 4-week basis. The shares have outperformed the S&P 500 by 2.3% in the past week but underperformed the index by 22.53% in the last 4 weeks.
    Pluristem Therapeutics, Inc. (NASDAQ:PSTI) rose 1.98% or 0.06 points in daily trade. The stock opened at $3.14 and increased volatility pushed the price to extremes of $3.14 and $3.08, before the session concluded the last trade at $3.09. The rising volatility also led to a sharp increase in volume which was recorded at 211,721 shares. The previous session of the stock had ended at $3.03. The yearly nadir of the share price is $2.32 and the yearly zenith is $4.36. The market cap of the scrip is $218 million and the company has 70,528,000 shares in free circulation.

    Sentiment: Strong Buy

  • dubi_calmy by dubi_calmy Apr 17, 2015 9:39 AM Flag

    In a research note issued to investors, Vernon Bernardino at MLV & Co Reiterated their Buy rating on Pluristem Therapeutics Inc. (NASDAQ:PSTI). The analyst placed a $6.00 price target on the stock which indicates a 105.48% upside to the last closing price.

  • [b]Conclusion[/b]

    Can-Fite currently trades with a basic market cap of only approximately $90 million. We believe that positive results from the Phase 2/3 psoriasis trial is likely to result in a revaluation of the company based on an increased likelihood of approval and a partnership deal with a larger pharmaceutical company that is likely to bring in non-dilutive capital the company can utilize to continue development in the other indications.

    We believe that, if approved, CF101 will be directly competing with Otezla® for psoriasis patients who have either failed biologic therapy or would like the convenience of an orally dosed medication, an indication that we conservatively believe could result in peak sales of $800 million. For point of reference, Celgene recently guided that Otezla® would be a $1.5 billion drug in 2017. Notwithstanding Celgene's bullish beliefs of Otezla®, if CF101 is an $800 million drug as we suspect, we believe right now it is worth approximately $85 million in value. We arrive at that number by assuming peak sales of $800 million takes place in 2025, with a 25% discount rate and 25% probability of success. Positive Phase 2b data coming in the next 1-2 weeks has the potential to double this valuation, as we would raise our likelihood of success to 50% for the Phase 3 program.

    The RA market is quite large, estimated to be approximately $38 billion in 2017, and we estimate that even with modestly less efficacy than the biologic treatments, an oral treatment for RA with a strong safety record and few side effects could likely generate peak revenues in excess of $1 billion. We believe this because of the personalized medicine approach Can-Fite is taking with CF101, based upon data showing that RA patients have increased A3AR expression compared to healthy controls (Madi et al., 2007), and the proof-of-concept data showing that screening patients for A3AR expression level results in a statistically significant difference in ACR20 between CF101 and placebo treated patients. Our valuation assumption for CF101 in RA is approximately $100 million, which we arrive at by forecasting approximately $1 billion in sales by 2025.

    Nexavar®, the only systemic treatment approved for HCC, generated over $1 billion in revenues in 2013, thus we forecast that even by going after a smaller patient population, those patients with advanced liver disease, CF102 could achieve peak revenues of $300 million. We are adding in another $40 million for value with CF102 given the peak sales assumptions and probability of success.

    [b]Summing up our analysis, we believe Can-Fite is worth approximately $225 million in value, or around 2.5x the current stock price.
    The primary risk to an investment in Can-Fite at this juncture is that the Phase 2/3 psoriasis trial fails, which would likely cause a steep drop in the stock price, or that the company is unable to find a suitable partnership to continue development of CF101 in psoriasis. This risk is somewhat mitigated by the fact that the company will be initiating a Phase 3 trial in RA later in 2015 and has also started a Phase 2 trial of CF102 in HCC. In addition to what we have discussed, the company is also completing preclinical studies on CF602 for the treatment of erectile dysfunction and the company's subsidiary, OpthaliX, Inc., is currently testing CF101 in a Phase 2 trial for the treatment of glaucoma, with results expected to be released in the second half of 2015.

  • Roth Capital affirms Can-Fite BioPharma Ltd. (NYSE: CANF) at Buy with a price target of $20 after the company announced that it has completed the development of a commercial predictive biomarker blood test kit for the A3 adenosine receptor (A3AR).

    Analyst Joseph Pantginis commented, We believe this is an important milestone because it further signals the potential of CANF being the first company able to prospectively identify patients for likely response in major inflammatory disorders. We believe the key proof of concept came from the previous positive randomized Phase II study in rheumatoid arthritis (RA).

    Can-Fite is moving quickly toward a pivotal data read out in 1Q15 with Phase II/III psoriasis data. We believe that the positive randomized Phase II RA data with CF101 and earlier data in psoriasis bode well for this study. The psoriasis data will consist of efficacy data from ~300 patients. Recall we already received a positive interim analysis for the first 100 patients. With randomized Phase II RA data in hand and psoriasis data coming shortly we believe the company is also poised for a significant partnership. The company has stated that it has been under CDA with multiple companies for a potential CF101 deal for some time now. We believe the psoriasis data could represent the final catalyst in signing the deal as it would emphasize the potential of CF101 in multiple indications.

  • Novartis exec David Epstein says having invested in Israel's Gamida Cell and BioLineRx,
    Novartis is hungry for more. Novartis also signed a deal with BiolineRX Ltd. (Nasdaq: BLRX);
    TASE:BLRX), under which BioLineRx will seek and develop Israeli technologies for Novartis.
    “In addition, we wanted to find a partner that has a deep familiarity with the Israeli market - with the start-ups and with the universities in Israel, and that is why we chose BioLineRx, which has been operating in Israel for a long time, in order to better connect with opportunities in Israel.”

    What is your impression of the two investments you have made so far?

    “The investments are new. Gamida has advanced a lot since we met, the team is very talented. The partnership with BioLineRx is fresher, but it has a lot of openness and wonderful accessibility. So, all in all, we have had a good start, but we are still in very early stages, particularly with regards to BioLineRx.”

    Are there more options on the table?

    “Novartis announced that it will carry out targeted acquisitions. In Israel, it will probably be primarily through BioLineRx. Under the terms of the investment in BioLineRx, the company is meant to take the money, identify the Israeli start-ups, and then acquire the rights to develop their technologies. We will be able to buy these technologies from them, if they advance well.

    (These are a few excperts from the globes newspaper article)

  • Reply to

    Roth recommendation

    by vm779460 Mar 12, 2015 3:34 AM
    dubi_calmy dubi_calmy Mar 12, 2015 10:18 AM Flag

    In a research note issued today, Roth Capital analyst Richard Baldry reiterated coverage with a Buy rating on shares of Top Image Systems (TISA), and a $7.50 price target following today’s news that TISA acquired eGistics, a cloud-based provider of document management and processing solutions primarily targeting the “eRemittance” payment processing space. The acquisition adds roughly 35% to TISA’s revenues and is expected to be accretive to earnings in the current year.

    Baldry commented: “The eGistics acquisition adds substantially to TISA’s scale, with eGistics reporting $10.6M in 2013 revenues versus a 1Q14 run-rate of $32M for TISA. Management expects the acquisition to be accretive to earnings in the current year, which could be an important sentiment catalyst, in our view, as recent investments to accelerate TISA’s growth have pressured near-term earnings and contributed to a 35% pullback to its shares”.

  • dubi_calmy by dubi_calmy Mar 27, 2015 9:07 AM Flag

    In a report released today, Richard Baldry from Roth Capital maintained a Buy rating on Top Image Systems (NASDAQ: TISA), with a price target of $7.50. The company’s shares opened today at $3.35.

  • Reply to

    Ophthalix / Eye-Fite is valued at $50 million

    by tflynn36 Mar 27, 2015 5:22 PM
    dubi_calmy dubi_calmy Mar 28, 2015 9:26 AM Flag

    Notwithstanding, if CANF submits positive results, OPLI
    might indeed hop to $50 million in a jiffy!

  • Reply to

    Ophthalix / Eye-Fite is valued at $50 million

    by tflynn36 Mar 27, 2015 5:22 PM
    dubi_calmy dubi_calmy Mar 28, 2015 7:03 AM Flag

    13.05 M according to Yahoo/OPLI key statistics

  • Reply to

    Any news in Israel?

    by richard8547 Mar 30, 2015 8:45 AM
    dubi_calmy dubi_calmy Mar 30, 2015 9:02 AM Flag

    None yet!

29.980.00(0.00%)Feb 26 4:00 PMEST